Pioglitazone Reduces Pulmonary Hypertension by Affecting Gut Microbiome
Author Information
Author(s): Zhang Zizhou, Liang Yaru, Mo Shaocong, Zhao Mingming, Li Yi, Zhang Chenting, Shan Xiaoqian, Liu Shiyun, Liao Jing, Luo Xiaoyun, Zhu Junqi, Wang Chen, Jiang Qian, Hou Chi, Hong Wei, Lai Ning, Chen Yuqin, Xu Lei, Lu Wenju, Wang Jian, Wang Zhongfang, Yang Kai
Primary Institution: Guangzhou Medical University
Hypothesis
This study aims to investigate the effects of pioglitazone on gut microbiome in pulmonary hypertension rat models and evaluate the therapeutic potential of probiotics.
Conclusion
Oral administration of pioglitazone protects against pulmonary hypertension by reshaping the gut microbiome and plasma metabolome.
Supporting Evidence
- Pioglitazone inhibited pulmonary hypertension pathogenesis in rat models.
- Probiotic supplementation partially alleviated pulmonary hypertension symptoms.
- Significant correlations were found between specific gut bacteria and protective metabolites.
Takeaway
Giving pioglitazone to rats helps their bodies fight a lung problem by changing the tiny bugs in their stomachs and the chemicals in their blood.
Methodology
The study used male Sprague Dawley rats, divided into groups, and treated with pioglitazone while assessing gut microbiome and plasma metabolome changes.
Potential Biases
Potential bias due to the use of a single animal model and the specific treatment regimen.
Limitations
The study was conducted on male rats, which may limit the generalizability of the findings to other populations.
Participant Demographics
Adult male Sprague Dawley rats, weighing 200-250g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website